14:57:23 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-20 Kvartalsrapport 2024-Q3
2024-08-28 Kvartalsrapport 2024-Q2
2024-05-28 Kvartalsrapport 2024-Q1
2024-05-15 Ordinarie utdelning ISAB 0.00 SEK
2024-05-14 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-11-22 Kvartalsrapport 2023-Q3
2023-08-29 Kvartalsrapport 2023-Q2
2023-05-31 Kvartalsrapport 2023-Q1
2023-05-15 Ordinarie utdelning ISAB 0.00 SEK
2023-05-12 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-22 Kvartalsrapport 2022-Q3
2022-08-29 Kvartalsrapport 2022-Q2
2022-06-08 Ordinarie utdelning ISAB 0.00 SEK
2022-05-23 Kvartalsrapport 2022-Q1
2022-05-06 Årsstämma 2022
2022-02-28 Bokslutskommuniké 2021
2021-11-24 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-06-22 Extra Bolagsstämma 2021
2021-06-09 Ordinarie utdelning ISAB 0.00 SEK
2021-06-08 Årsstämma 2021
2021-05-19 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-26 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-06-12 Extra Bolagsstämma 2020
2020-05-13 Ordinarie utdelning ISAB 0.00 SEK
2020-05-12 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-22 Årsstämma 2019
2019-05-16 Kvartalsrapport 2019-Q1
2019-05-10 Ordinarie utdelning ISAB 0.00 SEK
2019-02-21 Bokslutskommuniké 2018
2018-12-13 Extra Bolagsstämma 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-24 Ordinarie utdelning ISAB 0.00 SEK
2018-05-23 Årsstämma 2018
2018-05-16 Kvartalsrapport 2018-Q1
2018-02-22 Bokslutskommuniké 2017
2017-11-17 Kvartalsrapport 2017-Q3
2017-08-28 Kvartalsrapport 2017-Q2

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Inhalation Sciences Sweden, ISAB, är ett forskningsbolag. Idag innehas störst fokus mot framställning och utvecklande av laboratorieinstrument. Instrumenten används för att mäta partiklar i inandningsluften och hur luftens sammansättning påverkar lungorna. Bolaget säljer produkter under varierade varumärken, främst på den europeiska marknaden. Inhalation Sciences Sweden grundades 2004 och har sitt huvudkontor i Huddinge.
2023-05-25 08:30:00

(Stockholm, 25 May, 2023) Inhalation Sciences (ISAB) has been awarded 125,000 EURO for its role in the research project `New Inhalation Formulations for Improved Delivery of Antimicrobials' (APRINHA). ISAB is one of seven organizations collaborating on this project, including RISE (the Research Institutes of Sweden.) ISAB announced that it had collaborated with RISE on a joint funding proposal for the project on June 9, 2022. The project will run for 36 months. It is being coordinated by the University of Zurich (UZH).

The unmet need for a targeted, efficacious inhaled antibiotic treatment for the growing number of patients hospitalized with lower respiratory tract infections (LRTIs) has become increasingly clear following the Covid-19 pandemic. The APRINHA project aims to address that unmet need. It will develop new inhaled formulations of an antibiotic that can both treat LRTIs and help reduce antibiotic resistance. The new formulations aim to improve drug deposition, retention, and penetration.

The project will last 36 months. Seven organizations are part of the consortium taking part, including RISE, the Research Institute of Sweden. All bring outstanding expertise in inhalation and pulmonary drug delivery with strong track records in contributing to multidisciplinary cross-border research projects. In this project, ISAB will collaborate with the inhalation team at RISE and be using its in vivo PreciseInhale equipment in RISE research facilities to carry out pharmacokinetic (PK) studies of the new formulations.

Manoush Masarrat, CEO ISAB: "We are pleased to be playing a part and would like to thank the team at the Institute of Medical Microbiology at UZH for initiating and coordinating the project. The unmet need for better formulations of antibacterial inhalation products that are active against drug-resistant respiratory infections is urgent. This project addresses that need."

Read ISAB's June 9 2022 Press Release on its joint funding proposal to APRINHA with RISE here. (https://www.inhalation.se/investors/pressmeddelanden/?pressreleaseId=4286109)